Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV

Summary

A randomized, double-blind, placebo -controlled, phase IIb clinical trial to evaluate the efficacy, safety and immunogenicity of one or two doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years of age and older, living with HIV, on stable treatment, and virologically suppressed for at least 6 months Protocol number: FH-58

Timeline

Start

2021-06-24

Primary completion

2023-01-13

Completion

2023-01-13

Publications

• Cahn P, Barreto L, Figueroa MI, Fink V, Rolon MJ, Lopardo G, Cassetti I, Ceschel M, Patterson P, Gambardella L, Mernies G, Nava A, Gou J, Wang R, Zhu T, Halperin SA. Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH). PLoS One. 2025 Jun 11;20(6):e0312893. doi: 10.1371/journal.pone.0312893. eCollection 2025.

Drugs

Indications